Predicting the Response to Montelukast by Genetic Variation in Asthmatics

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

150 participants

Study Classification

INTERVENTIONAL

Study Start Date

2003-04-30

Study Completion Date

2006-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to examine a specific variation in the genetic code for an enzyme (LTC4 synthase) which plays an important role in the airway inflammation associated with asthma. We hypothesize that asthmatic patients with this variant gene will have a better response to montelukast than patients with the wild type gene, as measured by the ability of montelukast to protect against a hypertonic saline challenge.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Genetic Risk Factors for Severe Asthma

NCT00090740

Asthma

COMPLETED

Add-on Salmeterol Versus Montelukast in Arg/Arg-16 Asthmatics

NCT00655616

Asthma

COMPLETED NA

Chronic Asthma Study in 2- to 5-Year-Old Patients (MK0476-072 )

NCT00968201

Asthma

COMPLETED PHASE3

MK0524 Asthma POC Study (0524-008)(COMPLETED)

NCT00783601

Asthma

COMPLETED PHASE2

Prescribing Asthma Controller Medication According to Gene Status to Improve Quality of Life in Young People With Asthma

NCT02758873

Asthma

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Multiple genetic polymorphisms in the leukotriene pathway have been described but their clinical relevance is unclear. A single nucleotide polymorphism in the LTC4 synthase promoter region has been associated with increased LTC4 synthase mRNA and a trend toward improved bronchodilatory response to leukotriene modifiers in severe asthmatics. This study will examine mild to moderate asthmatics with the variant gene and evaluate the bronchoprotective response of montelukast in a double-blind, placebo-controlled cross-over fashion.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Asthma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Montelukast

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and female subjects, age 18-55
* Clinical history consistent with asthma
* Mild to moderate asthma as determined by pulmonary function tests--60% or higher of predicted FEV1 for age, sex and race.
* Response to hypertonic saline, which will be the main outcome variable measured.

Exclusion Criteria

* Smokers (total lifetime smoking history\>10 pack-years, any in the past year)
* Pregnant woman-if of childbearing age, not using an acceptable form of birth control.
* Use of a leukotriene modifier within the past month
* Use of inhaled or oral steroids within the past month.
* Emergency room visit for asthma exacerbation within the past 6 weeks.
* Intubation for asthma exacerbation in the past 10 years.
* Adverse reaction to inhaled beta-agonists in the past.
* No recent (past 48 hours) use of anticholinergics, theophylline, antihistamines, pseudoephedrine.
* Patients will also be asked not to use any short acting beta-agonists for 6 hours and long-acting beta-agonists for 48 hours before their initial visit (when pulmonary function evaluation will be performed).
* Lung disease other than asthma
* Significant medical illness other than asthma

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No